Last updated on November 2019

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Glomerular Basement Membrane | Glioblastoma Multiforme | Glioma
  • Age: Between 22 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Histologically confirmed GBM, WHO grade IV. GBM variants and secondary GBM are allowed in any recurrence (including multiple) and have been treated with radiation and chemotherapy.
  • Unequivocal evidence of tumor progression during prior bevacizumab treatment per RANO criteria.
  • Patient is a candidate for, and agrees to proceed with additional bevacizumab treatment.
  • Male or female at least 22 years of age or older.
  • Karnofsky Performance Scale (KPS) 60%.
  • Planned treatment with TTFields therapy.
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of treatment.
  • Participants of childbearing/reproductive potential must use effective contraception.
  • Participants must be able to understand and willing to comply with protocol requirements as assessed by the investigator.
  • Signed informed consent according to institutional guidelines prior to registration.

Exclusion Criteria:

  • Inability to undergo brain MRI due to medical or personal reasons.
  • Currently receiving investigational agents that are intended as treatments of recurrent GBM.
  • Skull defect such as missing bone or bullet fragments.
  • Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, heart attack within the previous 12 months, stroke (except for TIA) within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Intracranial hemorrhage except for tumor associated micro hemorrhage.
  • Women who are pregnant or breastfeeding.
  • Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, vagus nerve stimulator, and other implanted electronic devices in the brain or the spinal cord.
  • Tumor located entirely in the infratentorium.
  • History of hypersensitivity to hydrogel.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.